Schizophrenia Research
Volume 43, Issue 2 , Pages 91-95 , 16 June 2000

Decreased S100-beta protein in schizophrenia: preliminary evidence

  • Wagner F. Gattaz

      Affiliations

    • Laboratory of Neurosciences (LIM-27), Department and Institute of Psychiatry, Faculty of Medicine of the University São Paulo, 01060-970 São Paulo, Brazil
    • Corresponding Author InformationCorresponding author. Fax: +55-11-852-9029
    • ,
  • Diogo R. Lara

      Affiliations

    • Department of Biochemistry, ICBS, Federal University, Rio Grande do Sul, Brazil
    • ,
  • Helio Elkis

      Affiliations

    • Laboratory of Neurosciences (LIM-27), Department and Institute of Psychiatry, Faculty of Medicine of the University São Paulo, 01060-970 São Paulo, Brazil
    • ,
  • Luis V. Portela

      Affiliations

    • Department of Biochemistry, ICBS, Federal University, Rio Grande do Sul, Brazil
    • ,
  • Carlos A. Gonçalves

      Affiliations

    • Department of Biochemistry, ICBS, Federal University, Rio Grande do Sul, Brazil
    • ,
  • Adriano B. Tort

      Affiliations

    • Department of Biochemistry, ICBS, Federal University, Rio Grande do Sul, Brazil
    • ,
  • Jorge Henna

      Affiliations

    • Laboratory of Neurosciences (LIM-27), Department and Institute of Psychiatry, Faculty of Medicine of the University São Paulo, 01060-970 São Paulo, Brazil
    • ,
  • Diogo O. Souza

      Affiliations

    • Department of Biochemistry, ICBS, Federal University, Rio Grande do Sul, Brazil

Received 6 April 1999 ,Accepted 30 July 1999.

References 

  1. Azmitia EC, Griffin ST, Marshak DR, Van Eldik LJ, Whitaker-Azmitia PM. S100B and serotonin: a possible astrocytic–neuronal link to neuropathology of Alzheimer's disease. Prog. Brain Res. 1992;94:459–473
  2. Brunner J, Gattaz WF. Intracerebroventricular injection of phospholipase A2 inhibits apomorphine-induced locomotion in rats. Psychiatry Res. 1995;58:165–169
  3. Brunner J, Gattaz WF. Intracerebral injection of phospholipase A2 inhibits dopamine-mediated behavior in rats — possible implications for schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 1995;246:13–16
  4. Ciccarelli R, Casabona G, D'Alimonte I, Di Iorio B, Caciagli F, Nicoletti F. Stimulation of nerve growth factor and S100 protein production from rat cultured astrocytes by adenosine A1 and group II metabotropic glutamate receptors. Drug Dev. Res. 1998;43:51
  5. Deicken RF. Functional magnetic resonance imaging and magnetic resonance spectroscopy in schizophrenia. In:  Gattaz WF, Häfner  editor. Search for the Causes of Schizophrenia. vol. IV:New York: Springer; 1999;p. 307–322
  6. Fagnart OC, Sindic CJ, Laterre C. Particle counting immunoassay of S100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system. Clin. Chem. 1988;34(7):1387–1391
  7. Gattaz WF, Brunner J. Phospholipase A2 and the hypofrontality hypothesis of schizophrenia. Prostaglandins Leukotrienes Essent. Fatty Acids. 1996;55:109–113
  8. Gattaz WF, Cairns NJ, Levy R, Forstl H, Braus DF, Maras A. Decreased phospholipase A2 activity in the brain and in platelets of patients with Alzheimer's disease. Eur. Arch. Psychiatry Clin. Neurosci. 1996;246(3):129–131
  9. Gattaz WF, Hübner , Nevalainen TJ, Thuren T, Kinnunen PKJ. Increased serum phospholipase A2 activity in schizophrenia: a replication study. Biol. Psychiatry. 1990;28:495–501
  10. Gattaz WF, Köllisch M, Thuren T, Virtanen JA, Kinnunen PKJ. Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy. Biol. Psychiatry. 1987;22:421–426
  11. Gattaz WF, Maras A, Cairns NJ, Levy R, Forstl H. Decreased phospholipase A2 activity in Alzheimer brains. Biol. Psychiatry. 1995;37:13–17
  12. Gattaz WF, Steudle A, Maras A. Increased platelet phospholipase A2 in schizophrenia. Schizophr. Res. 1995;16:1–6
  13. Griffin WTS, Stanley EC, Ling C, White J, Macleod V, Perrot LJ, et al. Brain interleukin 1 and S100 immunoreactivity are elevated in Down syndrome and Alzheimer's disease. Proc. Natl. Acd. Sci. USA. 1989;86:7611–7619
  14. Hansson LO, Djuren E, Dijlai-Merzog R, Nilsson B, Hansson J. S100B: a prognostic marker in malignant melanoma. Clin. Chem. 1998;44:46–47
  15. Iager AC, Kirch DG, Wyatt RJ. A negative symptom rating scale. Psychiatry Res. 1985;16:27–36
  16. Ingebrigtsen T, Romner B. Serial S100 protein serum measurements related to early magnetic resonance imaging after minor head injury. J. Neurosurg. 1996;85:945–948
  17. Ingebrigtsen T, Romner B, Kongstad P, Langbakk B. Increased serum concentrations of protein S-100 after minor head injury — a biochemical marker with prognostic value?. J. Neurol. Neurosurg. Psychiatry. 1995;59:103–104
  18. Jankovic BD, Djordjijevic D. Differential appearance of autoantibodies to human brain S100 protein — neuron specific enolase and myelin basic protein in psychiatric patients. Int. J. Neurosci. 1991;60:119–127
  19. Lara DR, Souza DO. Schizophrenia: a purinergic hypothesis. Med. Hypoth. 1999;in press
  20. Marshak DR. S100 beta as a neurotrophic factor. Prog. Brain Res. 1990;86:169–181
  21. Missler U, Wandiger KP, Wiesmann M, Kaps M, Wesel K. Acute exacerbation of multiple sclerosis increases plasma levels of S-100 protein. Acta Neurol. Scand. 1997;96:142–144
  22. Newman-Tancredi A, Gauvadan S, Conte C, Chaput C, Touzard M, Verriele L, et al. Agonist and antagonist actions of antipsychotic agents at 5HT1A receptors: a (35S)GTPgammaS binding study. Eur. J. Pharmacol. 1998;335:245–256
  23. Noponen M, Sanfilipo M, Samanich K, Ryer H, Ko G, Angrist B, et al. Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biol. Psychiatry. 1993;34:641–649
  24. Ross BM, Hudson C, Erlich J, Warsh JJ, Kish SJ. Increased phospholipid breakdown in schizophrenia. Arch. Gen. Psychiatry. 1997;54:487–494
  25. Schäfer BW, Heizmann CW. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem. Sci. 1996;21:134–140
  26. Singh VK. Studies of neuroimmune markers in Alzheimer'disease. Mol. Neurobiol. 1994;1(3):73–81
  27. Slater P, Doyle CA, Deakin JF. Abnormal persistence of cerebellar serotonin-1A receptors in schizophrenia suggests failure to regress in neonates. J. Neural Transm. 1998;105:305–315
  28. Tacconi MT. Neuronal death: is there a role for astrocytes?. Neurochem. Res. 1998;23:759–765
  29. Van Eldik LJ, Zimmer DB. Secretion of S100 from rat c6 glioma cells. Brain Res. 1978;436:367–370
  30. Weinberger DR. From neuropathology to neurodevelopment. Lancet. 1995;346:552–557
  31. Whitaker-Azmitia PM, Murphy R, Azmitia EC. Stimulation of astroglial 5-HT1A receptors releases the serotonergic growth factor protein S100 and alters astroglial morphology. Brain Res. 1990;528:155–158
  32. Wiesmann W, Wandinger KP, Missler U, Eckhoff D, Rothermundt M, Arolt V, et al. Elevated plasma levels of S-100b protein in schizophrenia patients. Biol. Psychiatry. 1999;45:1508–1511
  33. Wu T, Angus CW, Yao XL, Logun C, Shalhamer JH. P11, a unique member of the S100 family of calcium-binding proteins, interacts with and inhibits the activity of the 85-kDA cytosolic phospholipase A2. J. Biol. Chem. 1997;272:17145–17153
  34. Zimmer DB, Cornwall EH, Landar A, Song W. The S100 protein family: history, function, and expression. Brain Res. Bull. 1995;37:417–429

PII: S0920-9964(99)00146-2

Schizophrenia Research
Volume 43, Issue 2 , Pages 91-95 , 16 June 2000

Article Tools

* Image Usage & Resolution